Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme

European Heart Journal

Volumn 22, Issue 7, 2001, Pages 554-572

  Kotseva, K ^a   Wood, D A ^a   De Backer, G ^a   De Bacquer, D ^a   Pyorala K ^a   Keil, U ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Euro Heart Survey; EUROASPIRE; Guidelines; Preventive cardiology

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EUROPE; FEMALE; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HUMAN; INFORMATION PROCESSING; INTERVIEW; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OBESITY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTILIPEMIC AGENTS; CORONARY DISEASE; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; INTERNATIONAL COOPERATION; LIFE STYLE; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 0034937093     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2610     Document Type: Article

References (50)

1. The burden of cardiovascular diseases mortality in Europe
2. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-Year results from 37 WHO MONICA Project populations
3. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
4. CHD prevention in clinical practice
5. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events)
6. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
7. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention
8. Coronary prevention guidelines - The clinical reality. A comparison of EUROASPIRE I and II surveys in 9 countries
9. The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient
10. Comprehensive risk reduction in coronary patients: Attainment of goals of the AHA Guidelines in U.S. patients
11. Screening of first degree relatives after the onset of coronary disease: A missed opportunity
12. Hypercholesterolaemia as a risk factor for coronary heart disease in the Asia-Pacific region: The ASPAC study
13. Prevalence of hypertension in CHD patients in the Asia-Pacific region: The ASPAC study
14. Prevalence of smoking among CHD patients in the Asia-Pacific: The ASPAC study
15. Secondary prevention of patients with acute coronary syndrome in France: Results of the PREVENIR survey
16. Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria
17. Risk indicators for recurrence among patients with coronary artery disease. Problems associated with their modification
18. Analysis of the degree of undertreatment of hyperlipidaemia and congestive heart failure secondary to coronary artery disease
19. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease
20. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease
21. Management of ischaemic heart disease in primary care: Towards better practice
22. Secondary prevention in coronary heart disease: Baseline survey of provision in general practice
23. Secondary prevention of coronary heart disease in primary care: A healthy heart initiative
24. La prevencion secundaria del infarto de miocardio en Espana. Estudio PREVESE
25. After 4S, CARE and LIPID - Is evidence-based medicine being practised?
26. The impact of landmark clinical trials on secondary prevention of acute myocardial infarction (AMI) in Spain. Prevese 98 study
27. Impact of smoking cessation and smoking interventions in patients with coronary heart disease
28. A clinical practice guideline for treating tobacco use dependence. A US public health service report
29. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy
30. Overweight and obesity: A major challenge for coronary heart disease secondary prevention in clinical practice in Europe
31. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations
32. Blood pressure and mortality among men with prior myocardial infarction
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study
34. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
35. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
36. Impact of diabetes on mortality after the first myocardial infarction
37. The impact of diabetes mellitus on survival after myocardial infarction: Can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study
38. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction
39. Definition, diagnosis and classification of diabetes mellitus and its complications
40. A desktop guide to Type 2 diabetes mellitus
41. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
42. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
43. Effects of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
44. Beta blockade after myocardial infarction: Systematic review and meta regression analysis
45. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials
46. Effects of an angiotensin-converting-enzime inhibitor, ramipril on cardiovascular events in high-risk patients
47. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
48. The therapeutic gap - Compliance with medication and guidelines
49. From best evidence to best practice - What are the obstacles?
50. International comparison of awareness and attitudes towards coronary risk factor reduction: The HELP study